# VEGI (Q-20): sc-13627



The Power to Question

## **BACKGROUND**

Vascular endothelial cell growth inhibitor (VEGI also known as TNFRSF15 or TL1), a member of the TNF superfamily, has a signaling pathway similar to TNF and is most likely a multifunctional cytokine. VEGI is found in brain, reproductive, and late developmental stage embryonic tissues and expressed predominantly in endothelial cells. VEGI is an angiogenesis inhibitor of the TNF family and functions in part by directly inhibiting endothelial cell proliferation. VEGI may act as an autocrine factor to induce apoptosis in endothelial cells via activation of multiple signaling pathways, including stress protein kinases as well as certain caspases.

## **REFERENCES**

- Tan, K.B., et al. 1997. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204: 35-46.
- 2. Haridas, V., et al. 1999. VEGI, a new member of the TNF family activates nuclear factor- $\kappa$  B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 18: 6496-6504.

#### CHROMOSOMAL LOCATION

Genetic locus: VEGI (human) mapping to 9g32.

### SOURCE

VEGI (Q-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the N-terminus of VEGI of human origin.

## **PRODUCT**

Each vial contains 200  $\mu g$  lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-13627 P, (100  $\mu g$  peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

#### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

# **APPLICATIONS**

VEGI (0-20) is recommended for detection of VEGI of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2  $\mu$ g per 100-500  $\mu$ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

VEGI (Q-20) is also recommended for detection of VEGI in additional species, including equine and bovine.


Suitable for use as control antibody for VEGI siRNA (h): sc-39846, VEGI shRNA Plasmid (h): sc-39846-SH and VEGI shRNA (h) Lentiviral Particles: sc-39846-V.

Molecular Weight of VEGI: 22 kDa.

#### **RECOMMENDED SECONDARY REAGENTS**

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/ 2.0 ml). 3) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

## **DATA**



VEGI (Q-20): sc-13627. Western blot analysis of human recombinant VEGI.

## **SELECT PRODUCT CITATIONS**

- Parr, C., et al. 2006. Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9: 73-81.
- Conway, K., et al. 2007. Vascular endothelial growth inhibitor represents an important target for therapeutic angiogenesis in the lower limb. International Wound Journal 4: 55-64.

## **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

## **PROTOCOLS**

See our web site at www.scbt.com or our catalog for detailed protocols and support products.



Try **VEGI (1A3): sc-53975**, our highly recommended monoclonal alternative to VEGI (Q-20).

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com